256 Participants Needed

Text-Based Intervention for HIV and Substance Use Disorders

(MATTER Trial)

Recruiting at 1 trial location
AB
CC
Overseen ByChristopher Chiu, MA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to help men who have sex with men (MSM) and gender minority individuals with HIV and substance use disorders (SUDs) manage their health better. It tests a new program called MATTER, which includes five text-enhanced therapy sessions to address stigma and shame, helping participants engage more effectively in HIV care. Participants will receive text messages and phone support to boost self-care and emotional awareness. The trial is ideal for those living with HIV and SUDs who experience feelings of stigma and struggle to control their HIV. As an unphased trial, this study offers a unique opportunity to explore innovative support methods for improving health management.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.

What prior data suggests that the MATTER intervention is safe for individuals with HIV and substance use disorders?

Research has shown that the MATTER program is designed to assist people with HIV and substance use issues. It employs text messages and online therapy sessions to address feelings of stigma and shame, which can hinder adherence to HIV treatment.

The MATTER program helps participants develop self-care skills, better understand their emotions, and learn self-compassion. This approach has been safely used in other areas. Since it doesn't involve drugs or medical procedures, it typically results in fewer side effects.

Although specific safety data for the MATTER program is not available, it is not a drug trial and involves therapy, making serious side effects unlikely. The methods are based on psychological practices that have been well-received in similar contexts.12345

Why are researchers excited about this trial?

Researchers are excited about the MATTER Intervention because it offers a novel approach by combining text-enhanced therapy with traditional one-on-one sessions, specifically targeting internalized stigma and shame among MSM and gender minority individuals with substance use disorders (SUDs). Unlike standard treatments that may focus solely on medication or in-person counseling, this intervention uses compassionate self-restructuring and daily text messages to reinforce self-compassion and emotional awareness over an extended period. This unique blend of behavioral therapy and digital support aims to improve HIV self-care and viral suppression by fostering greater self-efficacy and emotional resilience.

What evidence suggests that the MATTER intervention could be effective for HIV and substance use disorders?

Research has shown that text-based programs can help reduce drug use among people with HIV. One study found that these programs led to a noticeable drop in drug use. Another review found that combining treatments for HIV and drug misuse can improve health. In this trial, participants in the MATTER Intervention arm will receive a text-enhanced program designed to address emotional and behavioral issues, reducing stigma and shame. This approach aims to support individuals in maintaining consistent control over the virus by improving self-care and adherence to HIV treatment plans. Meanwhile, the Control Condition arm will involve prerecorded content related to local resources for substance use treatment and other services.56789

Are You a Good Fit for This Trial?

This trial is for men and gender minority individuals who have sex with men, are HIV positive with unsuppressed viral loads, and suffer from substance use disorders excluding tobacco, cannabis, or alcohol. Participants must experience internalized stigma related to their HIV status, substance use, sexual orientation or gender identity. They need to be adults able to consent in English and communicate in either English or Spanish. Access to a text-capable cell phone is required.

Inclusion Criteria

Have access to a cell phone with text capacity (study will supplement phones and plans as needed consistent with our pilot work)
I can read and understand English to give informed consent.
I am a man who has sex with men or identify as a gender minority.
See 6 more

Exclusion Criteria

I am a cisgender woman.
I am a cisgender heterosexual man.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the MATTER intervention, a 5-session text-enhanced psychobehavioral intervention delivered virtually to address internalized stigma and shame.

5 weeks
5 virtual therapy sessions

Follow-up

Participants are monitored for viral suppression and other outcomes at 6 and 12 months after the intervention.

12 months
6-month and 12-month follow-up visits

What Are the Treatments Tested in This Trial?

Interventions

  • Control Condition
  • MATTER Intervention
Trial Overview The MATTER intervention is being tested against a control condition. It's a virtual program of five sessions designed to help participants manage internalized stigma and shame associated with HIV and substance use by setting self-care goals, increasing awareness of thoughts and feelings without judgment (metacognition), fostering self-compassion, plus offering phone-based resource navigation.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Matter InterventionExperimental Treatment1 Intervention
Group II: Control ConditionActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

Published Research Related to This Trial

The MI+HealthCall intervention, which combines Motivational Interviewing with smartphone technology, showed high feasibility with a 95% daily use rate and excellent patient satisfaction (4.5 out of 5) among adults living with HIV.
Participants using MI+HealthCall experienced significantly greater reductions in drug use and spending compared to those receiving only Motivational Interviewing, indicating its potential effectiveness in addressing substance use issues that can hinder HIV treatment adherence.
HealthCall delivered via smartphone to reduce co-occurring drug and alcohol use in HIV-infected adults: A randomized pilot trial.Aharonovich, E., Stohl, M., Cannizzaro, D., et al.[2020]
The E-VOLUTION texting intervention, which sent automated reminders and support messages to 100 young adults living with HIV over 26 months, significantly improved adherence to medical appointments and viral load suppression, indicating its efficacy in enhancing HIV care.
Participants found the texting intervention acceptable, and the frequency of alerts triggered by their responses was positively correlated with better health outcomes, suggesting that this culturally responsive approach effectively engages youth in managing their health.
E-VOLUTION: A Text Messaging-Powered Intervention-Connection, Support, and HIV Eradication.Gerke, DR., Glotfelty, J., Schlueter, J., et al.[2021]
42% of non-treatment seeking individuals living with HIV (PLWH) and alcohol misuse agreed to participate in a computer-delivered brief alcohol intervention (CBI) in their primary care clinic, indicating a significant interest in addressing alcohol use.
Participants who agreed to CBI were more likely to have detectable viral loads and higher levels of alcohol use and mental health symptoms, suggesting that CBI effectively targets those most in need of support.
Implementation of Computer-delivered Brief Alcohol Intervention in HIV Clinical Settings: Who Agrees to Participate?Yang, C., Crane, HM., Cropsey, K., et al.[2022]

Citations

Substance Use Disorder Treatment OutcomesThe heterogeneous metrics and criteria used to assess the effectiveness of substance use disorders treatment hinders crossโ€study comparisons.
Integrating HIV and substance misuse services: a person ...In this Series paper we analyse existing literature and empirical evidence from scoping reviews on integration designs for the treatment of HIV ...
Meta-Analysis of Interventions for Reducing Number ...Overall, risk reduction intervention studies documented a reduction of drug abuse (mean ES: -0.26; 95% CI: -0.51, -0.01; P=0.04) among HIV-infected drug users, ...
Current Interventions for People Living with HIV Who Use ...The results from a sensitivity analyses among 317 participants who were living with HIV and reported engaging in alcohol use revealed that the ...
Substance Use Disorders and HIV/AIDS Prevention ...This article presents current data on HIV transmission and research evidence on prevention and intervention with substance abusers and highlights how ...
Substance Use Disorders and HIV/AIDS Prevention and ...This paper presents current data on HIV transmission and research evidence on prevention and intervention with substance abusers.
The effects of psychological functioning on substance use ...We tested the short-term (6 months) and long-term (12 months) effect of psychological distress on HIV-related and substance use-related outcomes ...
2022 National Survey on Drug Use and Health (NSDUH) ...The 2022 NSDUH Detailed Tables present national estimates of substance use, mental health, and treatment in the United States.
Evidence-Based Interventions for Preventing Substance Use ...This article reviews the epidemiology, etiologic risk and protective factors, and evidence-based approaches that have been found to be most effective in ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity